Purpose: Prospective analysis of local tumor control, survival, and treatment complications in 44 consecutive patients treated with fractionated photon and proton radiation for a chordoma or chondrosarcoma of the skull base.

Methods And Materials: Between December 1995 and December 1998, 45 patients with a median age of 55 years (14-85) were treated using a 201-MeV proton beam at the Centre de Protonthérapie d'Orsay, 34 for a chordoma and 11 for a chondrosarcoma. Irradiation combined high-energy photons and protons. Photons represented two-thirds of the total dose and protons one-third. The median total dose delivered within the gross tumor volume was 67 cobalt Gray equivalent (CGE) (range: 60-70).

Results: With a mean follow-up of 30.5 months (range: 2-56), the 3-year local control rates for chordomas and chondrosarcomas were 83.1% and 90%, respectively, and 3-year overall survival rates were 91% and 90%, respectively. Eight patients (18%) failed locally (7 within the clinical tumor volume and 1 unknown). Four patients died of tumor and 2 others of intercurrent disease. In univariate analysis, young age at time of radiotherapy influenced local control positively (p < 0.03), but not in multivariate analysis. Only 2 patients presented Grade 3 or 4 complications.

Conclusion: In skull-base chordomas and chondrosarcomas, the combination of photons with a proton boost of one-third the total dose offers an excellent chance of cure at the price of an acceptable toxicity. These results should be confirmed with a longer follow-up.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0360-3016(01)01634-0DOI Listing

Publication Analysis

Top Keywords

chordomas chondrosarcomas
12
total dose
12
photon proton
8
proton radiation
8
centre protonthérapie
8
protonthérapie d'orsay
8
chordoma chondrosarcoma
8
tumor volume
8
local control
8
patients
5

Similar Publications

Study Design: Systematic review.

Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment.

Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours.

View Article and Find Full Text PDF

Liquid Biopsy for Spinal Tumors: On the Frontiers of Clinical Application.

Global Spine J

January 2025

Combined Neurosurgical and Orthopedic Spine Program, Department of Orthopedics Surgery, University of British Columbia, Vancouver, BC, Canada.

Study Design: Narrative review.

Objectives: This article aims to provide a narrative review of the current state of research for liquid biopsy in spinal tumors and to discuss the potential application of liquid biopsy in the clinical management of patients with spinal tumors.

Methods: A comprehensive review of the literature was performed using PubMed, Google Scholar, Medline, Embase and Cochrane databases, and the review was limited to articles of English language.

View Article and Find Full Text PDF

Purpose:  Chordomas are malignant tumors of the axial spine and skull base, and they are notorious for their poor treatment response. Differentiating these tumors from comparatively less malignant chondrosarcomas is crucial for treatment and prognostication. Both tumor types differ in their developmental origin.

View Article and Find Full Text PDF

Chronic hearing loss turns out being a calcified chondroid mesenchymal neoplasm with FN1::FGFR2 fusion.

Eur Arch Otorhinolaryngol

October 2024

Barmherzige Brüder Klinikum St. Elisabeth Straubing, Klinik für Hals-Nasen-Ohren-Heilkunde mit Kopf-Hals- und plastischer Gesichtschirurgie, Straubing, Germany.

Article Synopsis
  • * The tumor, identified as a "calcified chondroid mesenchymal neoplasm" (CCMN) through molecular analysis, was surgically removed, showing extensive changes indicative of its aggressive nature.
  • * Follow-up imaging for over two years showed no residual tumor, but ongoing monitoring is crucial due to potential local recurrences; targeted therapies may be considered for any future recurrences involving the FGFR2 fusion.
View Article and Find Full Text PDF

Spinal chordoma and chondrosarcoma treatment experiences - a 20-year retrospective study from databases of two medical centers.

Sci Rep

October 2024

Divison of Neurosurgery, Departmet of Surgery, National Taiwan University Hospital, No.7, Chung Shan S. Rd. (Zhongshan S. Rd.), Zhongzheng Dist., Taipei, 100225, Taiwan (R.O.C.).

Article Synopsis
  • The study analyzed 48 patients with spinal chordoma and chondrosarcoma treated from 2001 to 2023, focusing on the type of surgical margins achieved during tumor removal.
  • Patients with negative or microscopically positive margins (R0/R1) had a significantly better overall survival (OS) and progression-free survival (PFS) compared to those with macroscopically positive margins (R2), implying that margin status is crucial for treatment outcome.
  • Radiation therapy (RT) did not enhance OS or PFS in either group, leading to the conclusion that en bloc resection surgery with a proper margin is the preferred treatment approach, while radiation may be an option for those unable to have surgery
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!